OR WAIT null SECS
August 20, 2020
BioMarin received the complete response letter for valoctocogene roxaparvovec, its gene therapy intended for treating severe hemophilia A.
The collaboration will increase the supply of the potential treatment to at least three and a half times the current capacity.
August 13, 2020
The company has launched its biosimilar rituximab, Ritucad, for the Indian market.
FDA has approved Evrysdi (risdiplam) for treating spinal muscular atrophy in adults and children.
Veklury (remdesivir) is an investigational antiviral drug that Gilead is developing to treat COVID-19.
August 11, 2020
The companies will collaborate on the manufacturing, clinical development, and regulatory activities for Novavax’s COVID-19 vaccine in Japan.
Questions about safety and efficacy surround Putin’s announced approval of a COVID-19 vaccine, with no supporting clinical trial results.
August 07, 2020
Roche has received approval from the European Commission for Rozlytrek (entrectinib), its newest anti-cancer drug, for two indications.
The European Medicines Agency recently approved two European Novartis sites in France and Switzerland for the commercial manufacturing of chimeric antigen receptor T-cell cell therapies.
The companies have agreements to supply its mRNA-based COVID-19 vaccine to Japan and Canada, pending regulatory approvals in those countries.